Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective
oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR) …

Purpose: Activation of MET oncogene as the result of amplification or activation mutation
represents an emerging molecular target for cancer treatment. We comprehensively studied …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …